Thalys Medical Technology Group Corporation

SHSE:603716 Stock Report

Market Cap: CN¥1.7b

Thalys Medical Technology Group Past Earnings Performance

Past criteria checks 0/6

Thalys Medical Technology Group's earnings have been declining at an average annual rate of -66.6%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 1.7% per year.

Key information

-66.6%

Earnings growth rate

-66.6%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate1.7%
Return on equity-18.2%
Net Margin-11.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Thalys Medical Technology Group Corporation (SHSE:603716) Shares Fly 26% But Investors Aren't Buying For Growth

Nov 20
Thalys Medical Technology Group Corporation (SHSE:603716) Shares Fly 26% But Investors Aren't Buying For Growth

Thalys Medical Technology Group Corporation (SHSE:603716) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Aug 12
Thalys Medical Technology Group Corporation (SHSE:603716) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Revenue & Expenses Breakdown

How Thalys Medical Technology Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:603716 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,897-21134047
30 Jun 241,971-16532947
31 Mar 242,047-14134145
31 Dec 232,006-15935643
30 Sep 232,076-15336440
30 Jun 232,170-15438832
31 Mar 232,174-19042628
31 Dec 222,309-15442429
30 Sep 222,536-5542526
30 Jun 222,552-5142731
31 Mar 222,662-3341034
31 Dec 212,600-5040035
30 Sep 212,5953032238
30 Jun 212,5525330334
31 Mar 212,3618828628
31 Dec 202,1255828319
30 Sep 201,8785030410
30 Jun 201,761622899
31 Mar 201,752642839
31 Dec 191,83111027211
30 Sep 191,69911226511
30 Jun 191,58510224710
31 Mar 191,417972308
31 Dec 181,317942157
30 Sep 181,2311102006
30 Jun 181,1351051918
31 Mar 181,018981717
31 Dec 17921941605
30 Sep 17787741384
30 Jun 17694701230
31 Mar 17652731150
31 Dec 16627691110
30 Sep 1660069990
31 Dec 1553061920
31 Dec 1444557790
31 Dec 1339249710

Quality Earnings: 603716 is currently unprofitable.

Growing Profit Margin: 603716 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 603716 is unprofitable, and losses have increased over the past 5 years at a rate of 66.6% per year.

Accelerating Growth: Unable to compare 603716's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 603716 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).


Return on Equity

High ROE: 603716 has a negative Return on Equity (-18.18%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:35
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Thalys Medical Technology Group Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yin YePing An Securities Co. Ltd.